Cybin Inc. (CYBN) |
|
0.3999 -0.01 (-2.46%)
|
01-27 16:00 |
|
Open: |
0.41 |
Pre. Close: |
0.41 |
|
High:
|
0.41 |
Low:
|
0.38 |
|
Volume:
|
1,210,223 |
Market Cap:
|
71(M) |
|
|
|
Technical analysis |
as of: 2023-01-27 4:43:40 PM |
|
Overall:
|
 |
| Stoxline posted a SELL today, same as yesterday. Downward movement continues. |
| Target: |
Six months: 0.57 One year: 0.72 |
| Support: |
Support1: 0.27 Support2: 0.22 |
| Resistance: |
Resistance1: 0.48 Resistance2: 0.62 |
| Pivot: |
0.44  |
| Moving Average: |
MA(5): 0.4  MA(20): 0.41
MA(100): 0.47 MA(250): 0.63 |
| MACD: |
MACD(12,26): 0 Signal(9): 0 |
| Stochastic oscillator: |
%K(14,3): 26 %D(3): 30.8 |
| RSI: |
RSI(14): 49.7 |
| 52-week: |
High: 1.15 Low: 0.26 |
| Average Vol(K): |
3-Month: 1,318 (K) 10-Days: 1,550 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ CYBN ] has closed above bottom band by 28.2%. Bollinger Bands are 17.7% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices. |
|
|
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
0.41 - 0.41 |
0.41 - 0.41 |
|
Low:
|
0.37 - 0.38 |
0.38 - 0.38 |
|
Close:
|
0.4 - 0.4 |
0.4 - 0.4 |
|
Company Description |
|
Cybin Inc., a biopharmaceutical company, focuses on developing psychedelic-based therapeutics. The company's development pipeline includes CYB003, a deuterated psilocybin analog to treat major depressive and alcohol use disorders; CYB004, a deuterated dimethyltryptamine for treating anxiety disorders; and CYB005, a phenethylamine derivative to treat neuroinflammation. It has also developed EMBARK, a psychedelic-assisted psychotherapy. The company is headquartered in Toronto, Canada. |
Headline News |
Thu, 26 Jan 2023
PsychedelicNewsBreaks - Cybin Inc. (NEO: CYBN) (NYSE American ... - MarketWatch
Thu, 26 Jan 2023
Psychedelic-Derived Medicines for Neurologic Conditions Fueling Large Revenue Growth in Projected $4 Billion Dollar Industry - Yahoo Finance
Thu, 26 Jan 2023
Cybin to Host Virtual R&D Day on February 28, 2023 - Business Wire
Wed, 18 Jan 2023
PsychedelicNewsBreaks - Cybin Inc. (NYSE American: CYBN) (NEO ... - MarketWatch
Wed, 18 Jan 2023
Psychedelic Stocks in Focus (LOBEF,ATAI,CMPS,MNMD,SEEL,CYBN) - BP Journal
Wed, 11 Jan 2023
Will Cybin Inc (CYBN) Beat the Rest of the Stocks in the Healthcare Sector? - InvestorsObserver
|
Financial Analysis |
| Price to Book Value: |
Outperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Underperform |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Underperform |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Underperform |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Neutral |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: AMEX |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. |
160 (M) |
| Shares Float |
113 (M) |
|
% Held by Insiders
|
21.6 (%) |
|
% Held by Institutions
|
16.9 (%) |
|
Shares Short
|
2,960 (K) |
|
Shares Short P.Month
|
2,690 (K) |
Stock Financials |
|
EPS
|
-0.31 |
|
EPS Est Next Qtl
|
0 |
|
EPS Est This Year
|
0 |
|
EPS Est Next Year
|
0 |
|
Book Value (p.s.)
|
0.62 |
|
Profit Margin (%)
|
0 |
|
Operating Margin (%)
|
0 |
|
Return on Assets (ttm)
|
0 |
|
Return on Equity (ttm)
|
0 |
|
Qtrly Rev. Growth
|
0 |
|
Gross Profit (p.s.)
|
-0.01 |
|
Sales Per Share
|
0 |
|
EBITDA (p.s.)
|
0 |
|
Qtrly Earnings Growth
|
0 |
|
Operating Cash Flow
|
-38 (M) |
|
Levered Free Cash Flow
|
0 (M) |
Stock Valuations |
|
PE Ratio
|
-1.3 |
|
PEG Ratio
|
0 |
|
Price to Book value
|
0.64 |
|
Price to Sales
|
0 |
|
Price to Cash Flow
|
-1.7 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
0 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
Your Ad Here
|
|
